Stocktoria
Niagen Bioscience, Inc. NAGE
Nasdaq · stock · Medicinal Chemicals & Botanical Products · website · IPO 2007-06-25
Niagen Bioscience, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $129.4M | $99.6M | $83.6M | $72.0M | $67.4M | $59.3M | $46.3M | $31.6M | $21.2M | — |
| Gross profit | $83.2M | $61.6M | $50.8M | $42.8M | $41.5M | $35.3M | $25.8M | $16.1M | $10.5M | $10.4M |
| R&D expense | $6.3M | $6.0M | $5.0M | $4.8M | $3.8M | $3.4M | $4.4M | $5.5M | $4.0M | $2.5M |
| Operating income | $16.3M | $7.7M | -$5.6M | -$18.6M | -$27.1M | -$19.9M | -$31.3M | -$33.2M | -$16.4M | -$2.9M |
| Interest expense | — | — | — | — | $55,000 | $71,000 | $847,000 | $79,000 | $153,000 | $333,286 |
| Income tax | $810,000 | $305,000 | $0 | — | — | — | — | — | $0 | $0 |
| Net income | $17.4M | $8.6M | -$4.9M | -$16.5M | -$27.1M | -$19.9M | -$32.1M | -$33.3M | -$11.4M | -$2.9M |
| EPS (diluted) | $0.20 | $0.11 | $-0.07 | $-0.24 | $-0.40 | $-0.33 | — | — | — | — |
| Operating cash flow | $13.5M | $12.1M | $7.1M | -$15.1M | -$24.2M | -$10.6M | -$20.4M | -$20.9M | -$9.8M | -$2.9M |
| Free cash flow | — | — | — | — | — | — | -$21.2M | -$22.2M | -$11.0M | -$4.4M |
| Cash & equivalents | — | $44.5M | $27.2M | $20.3M | $28.2M | $16.7M | $18.8M | $22.6M | — | — |
| Inventory | $20.4M | $9.2M | $14.5M | $14.7M | $13.6M | $11.7M | $11.5M | $8.2M | $5.8M | $7.9M |
| Total assets | $106.4M | $68.3M | $55.0M | $54.1M | $57.8M | $38.4M | $40.2M | $42.2M | $62.7M | $19.8M |
| Total liabilities | $29.9M | $22.2M | $26.5M | $25.4M | $26.1M | $21.9M | $19.8M | $15.1M | $8.9M | $9.8M |
| Shareholders' equity | $76.5M | $46.1M | $28.5M | $28.7M | $31.7M | $16.4M | $20.4M | $27.2M | $53.8M | $10.0M |
Growth · year-over-year · Revenue CAGR 25.4%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +29.9% | +19.2% | +16.0% | +6.8% | +13.8% | +28.0% | +46.7% | +48.8% | — | — |
| Net income growth | +103.3% | — | — | — | — | — | — | — | — | — |
| EPS growth | +81.8% | — | — | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.